Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Aggressive Hybrid Fund median (30 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 01 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 50 history starts 18 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | HDFC Hybrid Equity Fund |
|---|---|
| 01 Jan 2013 | ₹100.00 |
| 20 Feb 2014 | ₹93.80 |
| 11 Apr 2015 | ₹156.85 |
| 30 May 2016 | ₹141.26 |
| 19 Jul 2017 | ₹187.98 |
| 07 Sep 2018 | ₹189.21 |
| 27 Oct 2019 | ₹192.22 |
| 14 Dec 2020 | ₹222.73 |
| 02 Feb 2022 | ₹297.79 |
| 24 Mar 2023 | ₹307.69 |
| 12 May 2024 | ₹389.16 |
| 01 Jul 2025 | ₹450.57 |
| 20 Aug 2026 | ₹433.01 |
| Metric | HDFC · Direct NAV ₹125.39 High risk ★★☆☆☆ | Category median Aggressive Hybrid Fund · 30 funds |
|---|---|---|
| -2.32% | +4.10% | |
| +7.96% | +12.70% | |
| +9.75% | +11.11% | |
| +10.63% | +12.19% | |
| +11.35% | +12.98% | |
| +7.40% | — | |
| +12.55% | +14.27% | |
| +12.29% | +14.04% | |
| +12.46% | +13.80% | |
| Risk | ||
| 9.54% | 10.62% | |
| 0.15 | 0.58 | |
| 0.21 | 0.80 | |
| -33.56% | -28.65% | |
| Nifty 50 | — | |
| +0.01% | +4.10% | |
| 0.75 | 0.80 | |
| 77.2% | 92.5% | |
| 66.9% | 60.5% | |
| 1.11% | 1.00% | |
| ₹22,200Cr | ₹2,217Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| 2% | 37% | |
| Anupam Joshi | — | |
| 01 Jan 2013 | — | |
| 53 | — | |
| 35.8% | — | |
| 1.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.